WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1
- PMID: 31438961
- PMCID: PMC6704583
- DOI: 10.1186/s12943-019-1053-8
WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1
Abstract
Background: N6-methyladenosine (m6A) methylation, a well-known modification with new epigenetic functions, has been reported to participate in the tumorigenesis of hepatocellular carcinoma (HCC), providing novel insights into the molecular pathogenesis of this disease. However, as the key component of m6A methylation, Wilms tumor 1-associated protein (WTAP) has not been well studied in HCC. Here we investigated the biological role and underlying mechanism of WTAP in liver cancer.
Methods: We determined the expression of WTAP and its correlation with clinicopathological features using tissue microarrays and the Cancer Genome Atlas (TCGA) dataset. And we clarified the effects of WTAP on HCC cells using cell proliferation assay, colony formation, Edu assay and subcutaneous xenograft experiments. We then applied RNA sequencing combined with gene expression omnibus (GEO) data to screen candidate targets of WTAP. Finally, we investigated the regulatory mechanism of WTAP in HCC by m6A dot blot assay, methylated RNA immunoprecipitation (MeRIP) assay, dual luciferase reporter assay, RNA immunoprecipitation (RIP) assay and Chromatin immunoprecipitation (ChIP) assay.
Results: We demonstrated that WTAP was highly expressed in HCC which indicated the poor prognosis, and that WTAP expression served as an independent predictor of HCC survival. Functionally, WTAP promoted the proliferation capability and tumor growth of HCC cells in vitro and in vivo. Furthermore, ETS proto-oncogene 1 (ETS1) was identified as the downstream effector of WTAP. The m6A modification regulated by WTAP led to post-transcriptional suppression of ETS1, with the implication of Hu-Antigen R (HuR) as an RNA stabilizer. Then ETS1 was found to inhibit the progression of HCC and could rescue the phenotype induced by WTAP deficiency. Moreover, WTAP modulated the G2/M phase of HCC cells through a p21/p27-dependent pattern mediated by ETS1.
Conclusion: We have identified that WTAP is significantly up-regulated in HCC and promotes liver cancer development. WTAP-guided m6A modification contributes to the progression of HCC via the HuR-ETS1-p21/p27 axis. Our study is the first to report that WTAP-mediated m6A methylation has a crucial role in HCC oncogenesis, and highlights WTAP as a potential therapeutic target of HCC treatment.
Keywords: ETS1; Hepatocellular carcinoma (HCC); N6-methyladenosine (m6A); Wilms tumor 1-associated protein (WTAP).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures







Similar articles
-
High glucose facilitates hepatocellular carcinoma cell proliferation and invasion via WTAP-mediated HK2 mRNA stability.Mol Cell Biochem. 2025 Jul;480(7):4149-4168. doi: 10.1007/s11010-025-05235-w. Epub 2025 Mar 3. Mol Cell Biochem. 2025. PMID: 40032749
-
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1.Mol Cancer. 2020 Aug 10;19(1):123. doi: 10.1186/s12943-020-01239-w. Mol Cancer. 2020. PMID: 32772918 Free PMC article.
-
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.Cell Biol Int. 2020 Dec;44(12):2524-2531. doi: 10.1002/cbin.11459. Epub 2020 Sep 11. Cell Biol Int. 2020. PMID: 32869897
-
Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential.Biomolecules. 2022 Sep 2;12(9):1224. doi: 10.3390/biom12091224. Biomolecules. 2022. PMID: 36139062 Free PMC article. Review.
-
The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.Int J Biol Sci. 2021 Jul 22;17(12):3059-3079. doi: 10.7150/ijbs.62767. eCollection 2021. Int J Biol Sci. 2021. PMID: 34421350 Free PMC article. Review.
Cited by
-
MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma.Aging (Albany NY). 2022 Sep 10;14(18):7416-7442. doi: 10.18632/aging.204280. Epub 2022 Sep 10. Aging (Albany NY). 2022. PMID: 36098680 Free PMC article.
-
The Expressions and Functions of lncRNA Related to m6A in Hepatocellular Carcinoma from a Bioinformatics Analysis.Comput Math Methods Med. 2022 Oct 12;2022:1395557. doi: 10.1155/2022/1395557. eCollection 2022. Comput Math Methods Med. 2022. PMID: 36276996 Free PMC article. Review.
-
Readers of RNA Modification in Cancer and Their Anticancer Inhibitors.Biomolecules. 2024 Jul 22;14(7):881. doi: 10.3390/biom14070881. Biomolecules. 2024. PMID: 39062595 Free PMC article. Review.
-
Comprehensive analysis of N6-methyladenosine-related lncRNAs reveals distinct hepatocellular carcinoma subtypes with immunotherapeutic implications.Am J Transl Res. 2022 Sep 15;14(9):6504-6520. eCollection 2022. Am J Transl Res. 2022. PMID: 36247272 Free PMC article.
-
RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives.Nat Rev Gastroenterol Hepatol. 2024 Apr;21(4):267-281. doi: 10.1038/s41575-023-00884-y. Epub 2024 Jan 19. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38243019 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous